Search Results
Mar 26, 2026, 19:12 ET NXG NextGen Infrastructure Income Fund (NYSE: NXG) Announces Terms of Rights Offering
of equity and debt securities of infrastructure companies, including: (i) energy infrastructure companies, (ii) industrial infrastructure companies, (iii) sustainable infrastructure companies, and (iv) technology and communication infrastructure companies. The Fund will invest no more than 25% of its Managed
More news about: NXG Investment Management
Mar 26, 2026, 18:16 ET VERIGRAFT 將其首個有望根治慢性靜脈功能不全的療法，推進至關鍵的第 II/III 期臨床試驗
關鍵的第 II/III 期臨床試驗現正進行，目標於 2028 年取得美國及歐洲的市場核准這項「真正變革」的再生醫學，瞄準數以百萬計至今仍缺根治之法的患者。全生物性移植物可免除免疫抑制的需要，重拾自然機能該可擴展的製程受 92 項已授權專利保護預計到 2034 年，慢性靜脈功能不全市場規模將達 59.51 億美元*獲得現有投資者 1,000 萬美元融資支持瑞典哥德堡
More news about: VERIGRAFT
Mar 26, 2026, 17:00 ET TAE Technologies Advances Site Evaluation Process with Multi-State Visits Ahead of First Fusion Power Plant
related thereto; (ii) the outcome of any legal proceedings that may be instituted against TMTG or TAE following announcement of the proposed transaction; (iii) the inability to complete the proposed transaction due to the failure to obtain approval of the shareholders of TMTG or TAE, or other conditions to
More news about: TAE Technologies, Inc.
Mar 26, 2026, 16:37 ET QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
a primary control for AMT-130.Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.Timeline Deception: That defendants misled investors regarding the timing of a Biologics
More news about: Hagens Berman Sobol Shapiro LLP
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 26, 2026, 15:11 ET Keymed Biosciences gibt die Ergebnisse für das Geschäftsjahr 2025 und aktuelle Geschäftszahlen bekannt
First-in-Class-Antikörper-Wirkstoff-Konjugat (ADC) gegen Claudin 18.2): Nach der Auslizenzierung an AstraZeneca für die globale Entwicklung werden mehrere globale klinische Studien der Phase III zügig vorangetrieben. Im Februar 2026 wurde dem ersten Probanden in dieser klinischen Studie eine Dosis verabreicht, was eine Meilensteinzahlung auslöste.
More news about: Keymed
Mar 26, 2026, 15:08 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
Tras su concesión de licencia a AstraZeneca para su desarrollo global, se están llevando a cabo rápidamente múltiples ensayos clínicos globales de fase III. En febrero de 2026, se administró la primera dosis a un sujeto en este ensayo clínico, lo que activó un pago por hito. A principios de marzo de 2026,
More news about: Keymed
Mar 26, 2026, 13:30 ET Unlikely Collaborators Hosts Journalist and Author Eliot Stein
artists, and collaborators for conversations that challenge perspectives and deepen connections. Past Spark Salon speakers have included illusionist Harris III, psychologist Scott Barry Kaufman, PhD, nutrition therapist Kim Shapira, MS, RD, mythologist John Bucher, Harvard Business School professor and author
More news about: Unlikely Collaborators
Mar 26, 2026, 13:10 ET Norgine annuncia l'approvazione da parte di Swissmedic di PEDMARQSI® per la prevenzione della perdita dell'udito indotta da cisplatino nei bambini
autorizzazioni all'immissione in commercio di PEDMARQSI® si basavano sui dati in termini di sicurezza ed efficacia provenienti da due studi di fase III, randomizzati e in aperto: SIOPEL 6 (pivotal) e Clinical Oncology Group (COG) ACCL0431.2,3 In questi studi, il tiosolfato di sodio ha ridotto
More news about: Norgine
Mar 26, 2026, 12:46 ET Norgine anuncia la aprobación por parte de Swissmedic de PEDMARQSI®
pacientes.1Las autorizaciones de comercialización de PEDMARQSI® se basaron en datos de seguridad y eficacia de dos ensayos de fase III aleatorizados y abiertos: SIOPEL 6 (pivotal) y ACCL0431 del Clinical Oncology Group (COG).²,³ En estos estudios, el tiosulfato de sodio redujo significativamente
More news about: Norgine
Mar 26, 2026, 10:50 ET INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that monday.com Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
expansion within existing accounts and longer enterprise sales cycles, making monday.com's $1.8 billion 2027 target increasingly unlikely to be met; and (iii) defendants misled investors by providing the public with materially flawed statements of confidence and growth projections which did not account for
More news about: Robbins Geller Rudman & Dowd LLP
Mar 26, 2026, 10:03 ET Notice of Annual General Meeting in Securitas AB
www.securitas.com/agm2026 (ii) by telephone +46 10 470 31 30 or (iii) by mail to Securitas AB, "AGM" c/o Euroclear Sweden AB, Box 191, SE-101 23 Stockholm.On giving notice of attendance, the shareholder shall state
More news about: Securitas
Mar 26, 2026, 10:00 ET Labaton Keller Sucharow LLP Announces Notice of Pendency of Class Action, Proposed Settlement, and Motion for Attorneys' Fees and Expenses in In re PG&E Corporation Securities Litigation
Offerings: (i) April 2018 Offering, 3.95% Notes due 12/1/2047 (CUSIP 694308HY6); (ii) April 2018 Offering, 3.3% Notes due 12/1/2027 (CUSIP 694308HW0); (iii) December 2016 and March 2017 Offerings, 4% Notes due 12/1/2046 (CUSIP 694308HR1); (iv) March 2017 Offering, 3.3% Notes due 3/15/2027 (CUSIP 694308HS9);
More news about: Labaton Keller Sucharow LLP
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
action]On March 13, 2026, Immutep issued a press release "announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
$10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025. Then, on December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had failed to "achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Enphase Energy, Inc. and Certain Officers - ENPH
its ability to manage its channel inventory; (ii) Enphase overstated its ability to mitigate effects arising from the termination of the 25D Credit; (iii) accordingly, Enphase overstated its financial and operational prospects; and (iv) as a result, the Company's public statements were materially false
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (iii) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (iv) as a result, Defendants' public statements were materially
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against ODDITY Tech Ltd. and Certain Officers - ODD
the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (iii) accordingly, Defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel's regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Plug Power Inc. and Certain Officers - PLUG
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.On October 7, 2025, Plug Power issued
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Gemini Space Station, Inc. and Certain Officers - GEMI
platform; (ii) Gemini had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, Gemini's post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that Gemini
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Lakeland Industries, Inc. and Certain Officers - LAKE
these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (iii) Lakeland's business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification
More news about: Pomerantz LLP
Mar 26, 2026, 09:55 ET Notice of Annual General Meeting in Securitas AB
www.securitas.com/agm2026 (ii) by telephone +46 10 470 31 30 or (iii) by mail to Securitas AB, "AGM" c/o Euroclear Sweden AB, Box 191, SE-101 23 Stockholm.On giving notice of attendance, the shareholder shall state
More news about: Securitas
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
are advancing a Phase III clinical study to evaluate the efficacy and safety of Stapokibart in child subjects with moderate-to-severe AD, and as of the date of this announcement, patient enrollment is in progress. Additionally, in 2025, we continuously proceeded with a Phase III clinical study of Stapokibart
More news about: Keymed